Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Phio Pharmaceuticals Corp PHIO

Healthcare Biotechnology
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or... see more

Recent & Breaking News (NDAQ:PHIO)

Phio Pharmaceuticals and Karolinska Institutet Expand Collaboration to Develop Self-Delivering RNAi Immunotherapies for Treating Solid Tumors

PR Newswire November 21, 2019

Phio Pharmaceuticals Announces Closing of Public Offering of Common Stock

PR Newswire November 20, 2019

Phio Pharmaceuticals Announces Pricing of $1.0 Million Public Offering of Common Stock

PR Newswire November 18, 2019

Phio Pharmaceuticals Announces Proposed Public Offering of Common Stock

PR Newswire November 13, 2019

Phio Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

PR Newswire November 12, 2019

Phio Pharmaceuticals to Highlight Self-delivering RNAi Technology at SITC 2019

PR Newswire October 29, 2019

Phio Pharmaceuticals Announces Adjournment of 2019 Annual Meeting of Stockholders

PR Newswire October 11, 2019

Phio Pharmaceuticals Announces Research Collaboration with Carisma Therapeutics to Evaluate its Self-Delivering RNAi Technology to Enhance Macrophage-Based Adoptive Cell Therapy

PR Newswire September 9, 2019

Phio Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Healthcare Conference

PR Newswire September 3, 2019

Phio Pharmaceuticals and Helmholtz Zentrum München to Collaborate on Novel Targets for the Use of Self-Delivering RNAi In T Cell and NK Cell Adoptive Cell Therapy Therapeutics

PR Newswire August 15, 2019

Phio Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

PR Newswire August 12, 2019

Phio Pharmaceuticals to Present at Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum

PR Newswire May 20, 2019

Phio Pharmaceuticals Reports First Quarter 2019 Financial Results and Corporate Highlights

PR Newswire May 14, 2019